Canton Strategic Holdings completed the sale of Gravitas Life Sciences to Gravitas Collective under a Securities Purchase Agreement approved by an independent special committee. Consideration includes a $3.5 million unsecured seller note bearing 15% PIK interest, maturing July 17, 2029, plus potential development milestone payments. In a parallel step, Canton retained bispecific antibody assets via a Bill of Sale to its subsidiary Tharimmune SPV1, focusing its portfolio while monetizing the divested business.
Agreement 1: Canton Strategic Holdings Sells Gravitas Life Sciences; Receives $3.5M Seller Note at 15%
- Agreement type: Securities Purchase Agreement to sell all interests in Gravitas Life Sciences
- Counterparty: Gravitas Collective
- Signed / Effective: Jul 17 2026 / same
- Duration / Termination: N/A
- Reason: Divest non-core biotech unit and refocus resources
Agreement 2: Canton Strategic Holdings Receives $3.5M Unsecured Seller Note, 15% PIK, Due 2029
- Agreement type: Unsecured seller note, 15% PIK interest, maturing Jul 17 2029
- Counterparty: Gravitas Collective and Gravitas Life Sciences
- Signed / Effective: Jul 17 2026 / same
- Duration / Termination: 3 years
- Reason: Deferred consideration for Gravitas sale
Agreement 3: Canton Strategic Holdings Retains Bispecific Antibody Assets via Bill of Sale
- Agreement type: Bill of Sale, Assignment and Assumption for bispecific antibody assets
- Counterparty: Gravitas Life Sciences
- Signed / Effective: Jul 17 2026 / same
- Duration / Termination: N/A
- Reason: Retain key R&D assets after divestiture
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.